CN1296815A - 双氯酚酸钠滴眼液 - Google Patents
双氯酚酸钠滴眼液 Download PDFInfo
- Publication number
- CN1296815A CN1296815A CN 99123788 CN99123788A CN1296815A CN 1296815 A CN1296815 A CN 1296815A CN 99123788 CN99123788 CN 99123788 CN 99123788 A CN99123788 A CN 99123788A CN 1296815 A CN1296815 A CN 1296815A
- Authority
- CN
- China
- Prior art keywords
- diclofenac sodium
- diclofenac
- eye
- sodium
- name
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 12
- 229940012356 eye drops Drugs 0.000 title claims abstract 3
- 229960001193 diclofenac sodium Drugs 0.000 title claims description 9
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 title claims description 9
- 208000002177 Cataract Diseases 0.000 claims abstract description 4
- DOBUSJIVSSJEDA-UHFFFAOYSA-L 1,3-dioxa-2$l^{6}-thia-4-mercuracyclobutane 2,2-dioxide Chemical compound [Hg+2].[O-]S([O-])(=O)=O DOBUSJIVSSJEDA-UHFFFAOYSA-L 0.000 claims abstract description 3
- 229910021538 borax Inorganic materials 0.000 claims abstract description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004327 boric acid Substances 0.000 claims abstract description 3
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 206010015943 Eye inflammation Diseases 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229910000372 mercury(II) sulfate Inorganic materials 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- 229940006198 sodium phenylacetate Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000001524 infective effect Effects 0.000 abstract 1
- 229910000370 mercury sulfate Inorganic materials 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 206010022941 Iridocyclitis Diseases 0.000 description 4
- 201000004612 anterior uveitis Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010073679 Traumatic iritis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991237889A CN1180772C (zh) | 1999-11-23 | 1999-11-23 | 双氯芬酸钠滴眼液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991237889A CN1180772C (zh) | 1999-11-23 | 1999-11-23 | 双氯芬酸钠滴眼液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1296815A true CN1296815A (zh) | 2001-05-30 |
| CN1180772C CN1180772C (zh) | 2004-12-22 |
Family
ID=5282990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB991237889A Expired - Lifetime CN1180772C (zh) | 1999-11-23 | 1999-11-23 | 双氯芬酸钠滴眼液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1180772C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100362991C (zh) * | 2004-06-02 | 2008-01-23 | 刘继东 | 一种眼科用药物组合物 |
-
1999
- 1999-11-23 CN CNB991237889A patent/CN1180772C/zh not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100362991C (zh) * | 2004-06-02 | 2008-01-23 | 刘继东 | 一种眼科用药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1180772C (zh) | 2004-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3628679B2 (ja) | 目の炎症媒介疾患を治療するための移植片 | |
| CA1341418C (en) | Substantially-pure non-inflammatory hyaluronic acid | |
| JP2580458B2 (ja) | ヒアルロン酸の精製方法および眼科用の純粋なヒアルロン酸の分画 | |
| Garcia-Segura et al. | Steroids and neuroprotection: new advances | |
| DK2403493T3 (en) | Non-steroidal anti-inflammatory ophthalmic compositions | |
| US10398709B2 (en) | Compositions for the treatment of cataracts | |
| US20050245497A1 (en) | Treatment of ophthalmic conditions | |
| TWI816643B (zh) | 透過腦神經之藥理皮膚活化作用來治療與神經退化性疾病相關之症狀的技術 | |
| CA2498489A1 (en) | Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases | |
| WO2019097434A1 (en) | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders | |
| MX2021013695A (es) | Composición farmacéutica que contiene brexanolona, ganaxolona y zuranolona y usos de esta. | |
| JP5452932B2 (ja) | コレスト−４−エン−３−オンオキシムの新規誘導体、それを含む医薬組成物及び製造方法 | |
| Herbort et al. | Diclofenac drops to treat inflammation after cataract surgery | |
| Javadi et al. | Outcomes of phacoemulsification and in-the-bag intraocular lens implantation in Fuchs' heterochromic iridocyclitis | |
| Li et al. | A feasibility study of using biodegradable magnesium alloy in glaucoma drainage device | |
| CN1180772C (zh) | 双氯芬酸钠滴眼液 | |
| Meyer et al. | Efficacy of antiprostaglandin therapy in vernal conjunctivitis. | |
| WO1997004784A1 (fr) | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques | |
| CA2389025A1 (fr) | Composition hormonale a base d'un progestatif et d'un oestrogene et son utilisation | |
| Pereira et al. | Choroidal detachment after the use of topical latanoprost | |
| White et al. | Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation | |
| Pintiliuc et al. | Toxic anterior segment syndrome following EyePCL implantation in a hyperopic patient | |
| Aster et al. | Delay of corneal wound healing in patients treated with colchicine | |
| Uitto et al. | Effects of topical glucocorticoid medication on collagen biosynthesis in the dental pulp | |
| CN1092657A (zh) | 治痔散 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenyang Sinqi Pharmaceutical Co., Ltd. Assignor: Liu Jidong|Fan Haiyan Contract fulfillment period: 2008.11.19 to 2013.11.19 Contract record no.: 2008210000094 Denomination of invention: Diclofenac sodium eye drops containing no antimicrobial agent and preparation method thereof Granted publication date: 20041222 License type: Exclusive license Record date: 20081216 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.11.19 TO 2013.11.19; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081216 |
|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: FAN HAIYAN Owner name: SHENYANG XINGQI MEDICINE CO., LTD. Free format text: FORMER OWNER: LIU JIDONG Effective date: 20110926 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110926 Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Co-patentee before: Fan Haiyan Patentee before: Liu Jidong |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 110024 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: Shenyang Sinqi Pharmaceutical Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20041222 |
|
| CX01 | Expiry of patent term |